KALBITOR (ecallantide), from Takeda, is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Ecallantide is a plasma kallikrein inhibitor. In HAE, excess plasma kallikrein activity leads to overproduction of bradykinin, which causes the episodes of severe swelling characteristic of the disease. By inhibiting plasma kallikrein, ecallantide reduces bradykinin generation and helps control acute HAE attacks.
KALBITOR may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.
KALBITOR is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).
Indian Pharma Network (IPN) can source KALBITOR from Takeda’s authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.
For KALBITOR cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.
KALBITOR treats acute attacks of hereditary angioedema (HAE) in patients 12 years and older.
KALBITOR is manufactured by Takeda Pharmaceuticals.
No — due to the risk of anaphylaxis, KALBITOR must be administered by a healthcare professional with appropriate medical support available.
Cost depends on quantity and sourcing logistics — share your prescription with IPN for a quote.
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.
